

Peer Review File

Article information: <https://dx.doi.org/10.21037/tbcr-23-45>

Reviewer Comments

Reviewer A

Comment 1: In the enclosed manuscript, authors commented on an article from a recent retrospective study comparing abemaciclib vs. tucidinostat in patients with metastatic hormonal receptor-positive and HER2-negative breast cancer who progressed with CDK4/6 inhibitors (Yuan Y et al. ref. 11). The editorial commentary is well written and nicely pointed what we can learn from the results of the study, I think editorial commentary is suitable for publication in Translational Breast Cancer Research without any revisions, I think.

Reply 1: We appreciate the positive comments from Reviewer A regarding the well-written editorial commentary. We are pleased to hear that it is suitable for publication in Translational Breast Cancer Research.

Reviewer B

Comment 1: Excellent summary of the retrospective study's results, with detailed implications of the results and the bias that this type of study might have

Reply 1: Regarding Reviewer B's feedback, we are grateful for the acknowledgment of our detailed summary of the retrospective study's results and the implications discussed.

Reviewer C

Comment 1: This is a well-written editorial to go with the article by Yuan Yang et al. The authors should consider recent data presented at ASCO 2023 from the SONIA trial showing the efficacy of single-agent ET in the first line followed by combined CDK 4/6 + fulvestrant in the second line.

The authors should refer to recent data on antibody-drug conjugate as a potential treatment option after progression on CDK 4/6 inhibitors. There are also recent data on the value of PIK3CA inhibitors, AKT, and mTOR inhibitors following CDK 4/6 progression.

Reply 1: Reviewer C's suggestions are insightful, and we agree that incorporating recent data on antibody-drug conjugates, PIK3CA inhibitors, AKT, and mTOR inhibitors after CDK 4/6 progression, would enhance the completeness of our discussion. A discussion paragraph has been added (please refer to the “track changes” version of the editorial).